Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01148862 · ClinicalTrials.gov registry record · NA

Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System

A NA study of Type 1 Diabetes Mellitus, sponsored by Medtronic Diabetes.

Completed
Registry status
NA
Development phase
50
Enrollment target
5
Study locations

NCT01148862: Completed NA study of Type 1 Diabetes Mellitus, sponsored by Medtronic Diabetes.

NCT01148862 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Medtronic Diabetes. The registered enrollment target is 50 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01148862, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Medtronic Diabetes.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise. The study will consist of a total of 50 subjects, age 16 through 60 years with Type 1 Diabetes Mellitus.

Primary Outcome

Duration (minutes) of induced hypoglycemia (YSI \< 70 mg/dL)

Conditions Studied

Type 1 Diabetes Mellitus

Interventions

  • DEVICE The MiniMed Paradigm® X54 System

Study Locations (5)

California

  • AMCR Institute - Escondido
  • Stanford University - Stanford

Colorado

  • Barbara Davis Center of Childhood Diabetes - Aurora
  • Barbara Davis Center for Childhood Diabetes - Denver

Washington

  • Rainier Clinical Research Institute - Renton

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-06
Est. Completion 2011-11
Phase NA
Medtronic Diabetes

9 total trials

What the finished NCT01148862 record still lists

NCT01148862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which The MiniMed Paradigm® X54 System is the first listed.

NCT01148862 lists 5 locations in 3 states (California, Colorado, Washington).

Frequently Asked Questions

What is clinical trial NCT01148862 about?

NCT01148862 is a clinical study titled "Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System". The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise. The study will consist of a total of 50 subjects, age 16 through 60 years with Type 1 Diabetes Melli...

What is the current status of trial NCT01148862?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2010-06. Estimated completion is 2011-11.

What conditions does trial NCT01148862 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT01148862?

The interventions under investigation include: The MiniMed Paradigm® X54 System (DEVICE).

Who is sponsoring clinical trial NCT01148862?

This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01148862 being conducted?

This trial has 5 study locations across California, Colorado, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01148862's enrollment target sits among peer trials

50 52nd of 112 higher than 57 of 112 other Type 1 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01148862, the US trial registry maintained by the National Library of Medicine. NCT01148862 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.